marijuana use has risen in past decadesarticularly among black teens. ur analysis shows that public health campaigns are workingewer teens are smoking cigarettes,
which will go a long way toward clearing the virus. She also believes HIV vaccines in development could give patients an extra edge.
Even a vaccine that isn 100 percent effective at preventing transmission could boost a patient ability to destroy reactivated virus. However,
and Mental health (CAMH) in Toronto have found a possible link between inflammation in the brain and clinical depression.
and standard of care for mental health issues. The results from this study, published today in JAMA Psychiatry in an article entitled ole of Translocator Protein Density,
"says Jeffrey Meyer, M d.,Ph d.,of CAMH's Campbell Family Mental health Research Institute and senior author of the study."
Also yesterday, Johnson & johnson (J&j) joined the Yale Open Data Access (YODA) Project in agreeing to share data from clinical trials for medical devices and diagnostics.
or deny requests from investigators for de-identified patient data associated with the pharmaceutical, medical device,
or otherwise harm public health? whether through inadvertent errors in data analysis or, in the U s.,the prospect of monetary gain through qui tam lawsuits, the report stated.
Germany Institute for Quality and Efficiency in Health care (IQWIG) applies eference pricing setting reimbursements for new drugs at the same level as the best existing comparator unless the new drugs show superiority to that comparator;
"It is a threat to public health we take very seriously, and there currently is no treatment or vaccine.
We continue to study the virus to improve our understanding of how it works and ways to prevent its spread."
researchers from the Harvard T. H. Chan School of Public health have discovered what they believe will become an indispensable new target for the development of antimalarial drug therapies.
particularly in light of the huge disease burden of malaria,"explained senior author Manoj Duraisingh, Ph d.,professor of Immunology and Infectious diseases at the T. H. Chan School of Public health."
#Dissolvable Microneedles May Herald New Age of Vaccine Delivery Scientists from Osaka University report that flu vaccines delivered using microneedles that dissolve in the skin can protect people against infection even better than the standard needle-delivered vaccine.
The authors of the study (linical study and stability assessment of a novel transcutaneous influenza vaccination using a dissolving microneedle patch,
say their dissolvable patch could make vaccination easier, safer, and less painful. According to the World health organization, immunization prevents an estimated 2 million deaths every year.
The continued threat of pandemics such as H1n1 swine flu and emerging infectious diseases such as Ebola makes vaccine development and mass vaccination a priority for global healthcare.
Most vaccines are injected under the skin or into the muscle using needles. While this is an effective delivery method,
"Our novel transcutaneous vaccination using a dissolving microneedle patch is the only application vaccination system that is readily adaptable for widespread practical use,
we believe it will be particularly effective in supporting vaccination in developing countries.""The new microneedle patch (Microhyala) is dissolvable in water.
taking the vaccine with them. The researchers compared the new system to traditional needle delivery by vaccinating two groups of people against three strains of influenza:
and B. None of the subjects had a bad reaction to the vaccine, showing that it is safe to use in humans.
people given the vaccine using the microneedles had an immune reaction that was equal to or stronger than those given the vaccine by injection."
just as effective as the needle-delivered flu vaccines, and in some cases even more effective,"said Dr. Nakagawa.
we think it could bring about a major change in the way we administer vaccines globally, "said Dr. Nakagawa a
#Biopharma Demand Is Driving the Cell Culture Market The production of biologic therapies such as vaccines, blood factors,
Market Drivers An important driver of the cell culture market is the production of seasonal influenza vaccines,
as well as pandemic vaccine candidates. Seasonal influenza vaccines have traditionally been produced using egg-based technology. However, this labor-intensive approach to vaccine development is currently being replaced by cell-culture systems.
Prefluce, the first cell culture-based vaccine, received European approval in March 2011 and was available for the 2011012 influenza season in the 13 participating European union countries.
On November 20 2012, the U s. Food and Drug Administration approved the use of Flucelvax, which is the first U s.-licensed (trivalent inactivated) influenza vaccine manufactured using cell culture technology.
Stem cell research will also add to the robust growth of the cell culture market. The growing use
and diverse applications of stem cells are having a significant impact on the media market,
#Merck-Newlink Genetics Ebola Vaccine Shows 100%Efficacy in Phase III Trial Merck & co. and Newlink Genetics said today that a single dose of their Ebola vaccine candidate rvsv
-ZEBOV showed 100%efficacy in an analysis of interim data from a Phase III ring vaccination trial in Guinea.
According to those findings, all individuals who received the vaccine were protected against Ebola virus infection within 6 to 10 days of vaccination. he results of this interim analysis indicate that rvsv-ZEBOV might be highly efficacious and safe in preventing Ebola virus disease
when delivered during an Ebola virus disease outbreak via a ring vaccination strategy, the study team concluded.
and July 20, 2015,4, 123 people were assigned randomly to immediate vaccination with rvsv-ZEBOV, while 3, 528 people were assigned randomly to delayed vaccination during the trial, named bola ça suffit, French for bola,
that enough. n the immediate vaccination group, there were no cases of Ebola virus disease with symptom onset at least 10 days after randomization,
whereas in the delayed vaccination group there were 16 cases of Ebola virus disease from seven clusters,
showing a vaccine efficacy of 100%,the researchers added. The international team carrying out the trial included researchers from the World health organization, the Norwegian Institute of Public health, the Health Ministry of Guinea,
and Médecins sans Frontières. he extraordinary efforts of the team in Guinea and other experts have yielded interim results that suggest a potential role for our rvsv-ZEBOV vaccine in the fight against Ebola disease, Roger
M. Perlmutter, M d.,Ph d, . president of Merck Research Laboratories, said a statement. Added Charles J. Link Jr.
M d.,Newlink Geneticschairman, CEO, and CSO: e hope that the interim data published today contribute to the successful registration of our vaccine candidate,
which we believe can play an important part in diminishing the threat of Ebola. The Guinea trial is one of three ongoing studies in
The Sierra leone Trial to Introduce a Vaccine against Ebola (STRIVE) Phase III study being conducted by the Sierra leone College of Medicine and Allied Health Sciences, Sierra leone Ministry of Health,
The Partnership for Research on Ebola Vaccines in Liberia (PREVAIL) Phase II study being conducted by a Liberia-NIH partnership in Liberia.
To date, the rvsv-ZEBOV vaccine has been administered to more than 9, 000 people in Phase I, II,
Vaccinated individuals have been shown to develop antibodies against the Ebola virus, but the significance and durability of this immune response have not been determined. rvsv-ZEBOV was engineered initially with support from the Public health Agency of Canada
and licensed to Newlink Genetics. To produce the vaccine, the vesicular stomatitis virus was weakened by removing a gene
and replacing it with a single Ebola virus gene that alone cannot cause the disease. In November 2014
Newlink also said it was tiered eligible for royalties on sales of the vaccine n certain markets, subject to certain conditions.
and the Public health Agency of Canada in helping conduct the studies have been NIH and its National Institute of Allergy and Infectious diseases,
Major funding for these studies has come from sources that include the U s. Department of defense Defense Threat Reduction Agency and Joint Vaccine Acquisition Program, the U s. Department of health and Human Service Biomedical Advanced Research Development Authority,
and research related to the Ebola vaccine candidate, but primarily due to clinical trial expenses related to its pipeline of product candidates, including its Hyperacute immunotherapy cancer programs and its IDO pathway inhibitor (indoximod) programs
or READ more at Daily mail) Pass on the Good Newsbelow) TAGSBREAKTHROUGHHEALTHINNOVATIONMEDICALSCIENCEWELLNESS Cuban Cancer Vaccine Could Soon be Available in U s. May 20,
#World First Malaria Vaccine Approved and it Will be Not-for-Profit The world first malaria vaccine has been given approval by a European medical agency for future use in Sub-saharan africa, where more than a quarter million children under the age of five die every year from the disease.
European regulators examined phase III clinical trial results involving more than 16,000 young children conducted by research centers in eight African countries (Burkina faso, Gabon, Ghana, Kenya, Malawi, Mozambique, Nigeria
Glaxosmithkline Vice president for Africa told CNN. t is the first time anyone ever has been able to make a vaccine against a parasite.
Perhaps most impressive, Glaxosmithkline, the pharmaceutical company that worked on this vaccine for 30 years, and received $200 million from the Gates Foundation, is making RTS, S available as a nonprofit drug.
with all that money going back into further research for a malaria vaccine that could be even more effective.
and expects to invest a further $200 to $250 million until the vaccine is ready for market.
With this approval from the European Medicines Agency Friday, the vaccine next will be considered by the World health organizations,
and if they will use the vaccine, along with current Malaria prevention techniques, like bed nets. 80%of the children involved in the clinical trials were protected also by insecticide treated bed nets.
malaria cases were reduced by almost half in children aged 5-17 months at the time of first vaccination and by 27%in infants aged 6-12 weeks.
000 clinical malaria cases were prevented over the study period for every 1, 000 children vaccinated
organic products that present little or no health risk. These molecules are also highly stable, even at fairly high temperatures,
One company displayed a prototype of a 3d-printed medical device that can automatically stitch up patients after surgery.
"said Salman Bakht, the chief technology officer at Health care Originals, which makes a new asthma monitor called the Adamm.
#Shaping Implantable Medical devices to Avoid Immune system Tiny medical implants that can ferry drugs, cells, or other therapies safely to sites of disease are already seeing the light of day.
showed applying small quantities of antibiotic to the surface of medical devices, from small dental implants to hip replacements, could protect patients from serious infection.
Treating the surface of medical devices would have a greater impact on patients considered at high risk of infection such as trauma victims from road traffic collisions or combat operations,
eep bone infections associated with medical devices are increasing in number, especially among the elderly. s well as improving the quality of life,
Administering a vaccine to protect against infection would overwhelm the patient's immune system. However, if he or she has the option of receiving an antiviral to eliminate the infection,
News and information A step towards a type 1 diabetes vaccine by using nanotherapy June 10th, 2015investigation of Optical Properties of Quantum dots in Presence of Magnetic, Electrical Fields June 10th,
2015discoveries A step towards a type 1 diabetes vaccine by using nanotherapy June 10th, 2015investigation of Optical Properties of Quantum dots in Presence of Magnetic, Electrical Fields June 10th,
2015announcements A step towards a type 1 diabetes vaccine by using nanotherapy June 10th, 2015investigation of Optical Properties of Quantum dots in Presence of Magnetic, Electrical Fields June 10th,
2015interviews/Book reviews/Essays/Reports/Podcasts/Journals/White papers A step towards a type 1 diabetes vaccine by using nanotherapy June 10th,
where the local health care infrastructure might not be able to support the level of research
#Bonelike 3-D silicon synthesized for potential use with medical devices: Semiconducting silicon spicules engage tissue like a bee stinger Abstract:
Researchers have developed a new approach for better integrating medical devices with biological systems. The researchers, led by Bozhi Tian,
2015bonelike 3-D silicon synthesized for potential use with medical devices: Semiconducting silicon spicules engage tissue like a bee stinger July 8th,
#Freshly squeezed vaccines (Nanowerk News) MIT researchers have shown that they can use a microfluidic cell-squeezing device to introduce specific antigens inside the immune systems B cells,
and implementing antigen-presenting cell vaccines. Such vaccines, created by reprogramming a patients own immune cells to fight invaders,
hold great promise for treating cancer and other diseases. However, several inefficiencies have limited their translation to the clinic,
While most of these vaccines are created with dendritic cells, a class of antigen-presenting cells with broad functionality in the immune system,
A new vaccine-preparation approach Dendritic cells are the most naturally versatile antigen-presenting cells.
when for cell-based vaccines: They have a short lifespan, they do not divide when activated,
which has limited options for B-cell-based vaccine programming. Using Cellsqueeze circumvents this problem and by being able to separately configure delivery and activation,
researchers have greater control over vaccine design. Gail Bishop, a professor of microbiology at the University of Iowa Carver School of medicine and director of the schools Center for Immunology and Immune-Based Diseases, says that this paper presents a creative new approach with considerable
potential in the development of antigen-presenting cell vaccines. The antigen-presenting capabilities of B cells have often been underestimated,
in this new study, demonstrates promise as a versatile platform for creating more effective cell-based vaccines.
Future steps The researchers say they now plan to refine their B-cell-based vaccine to optimize distribution and function of the immune cells in the body.
A b-cell-based approach could also reduce the amount of patient blood required to prepare a vaccine.
patients receiving cell-based vaccines must have drawn blood over several hours each time a new dose must be prepared.
and cost required to engineer cell-based vaccines. We envision a future system, if we can take advantage of its microfluidic nature,
run it through a bedside device that has the antigen you want to vaccinate against, and then youd have the vaccine,
Szeto says s
#Nanotechnology helps protect patients from bone infection Leading scientists at the University of Sheffield have discovered nanotechnology could hold the key to preventing deep bone infections,
showed applying small quantities of antibiotic to the surface of medical devices, from small dental implants to hip replacements, could protect patients from serious infection.
Treating the surface of medical devices would have a greater impact on patients considered at high risk of infection such as trauma victims from road traffic collisions or combat operations,
eep bone infections associated with medical devices are increasing in number, especially among the elderly. s well as improving the quality of life,
Air pollution is the world largest single environmental health risk, causing one in every eight deaths according to figures released last year by the World health organization.
A team of undergraduate students also contributed to an early glove design as part of his ES227 Medical device Design Course.
to $289 billion annually in unnecessary health care costs from additional hospital visits and other issues.
and transparent material perfect for everything from water bottles to medical devices. But recently, that soaring success has soured:
and an expert in nanoengineering for health care and medical applications. hen you think about field deployment,
foldable and lightweight energy storage device that provides the building blocks for next-generation batteries needed to power wearable electronics and implantable medical devices (ACS Central Science,"Self-Assembled Multifunctional Hybrids:
#New material opens possibilities for super-long-acting pills (Nanowerk News) Medical devices designed to reside in the stomach have a variety of applications,
Possessing emergency first aid and medical skills was also extremely important, as many people suffered injuries from being hit by debris in flood waters.
They've recently even decided that California should cover the health care costs of the children of illegal immigrants.
free health care for everyone, unlimited debt spending on entitlement programs, magical waterfalls of free H2o falling out of the clouds, and so on.
as guinea pigsvicious vaccine culture war now being waged against informed, intelligent Americans who seek to protect their children from deadly side effects131 Ways for an Infant to Die:
Vaccines and Sudden Deathnaturalnews exclusive: Michigan government unleashes armed raids on small pig farmers, forces farmer to shoot all his own pigs/**CONFIGURATION VARIABLES:
Professor Hugh Perry, who chairs the Medical Research Council Neuroscience and Mental health Board said: his work builds on our understanding of the genetic causes of schizophrenia unravelling how a combination of genetic faults can disrupt the chemical balance of the brain. cientists in the UK,
as part of an international consortium, are uncovering the genetic causes of a range of mental health issues, such as schizophrenia. n the future,
said Michael Salter, M d.,Ph d.,Head and Senior Scientist, Neuroscience & Mental health at Sickkids and Professor at The University of Toronto,
as a result of an infection and those triggered by a vaccine. Instead the technique might be useful in outbreaks of new viruses. Understanding how our immune system responds to other viral fragments might reveal clues as to
and Italy, aiming to compare its readings with those from traditional medical devices. Consumer technology that can read signals from the body to interpret underlying physical
and mental health is on the cusp of becoming part of everyday life. For example, Cardiio, originally developed at the Massachusetts institute of technology
The vaccination drive has been dogged by political corruption rumours the vaccine was contaminated with HIV and violence nine health workers were killed by terrorist group Boko Haram in 2013.
Nigeria has come close to eradicating the disease several times before, only for it to re-emerge. But this is the longest the country has gone without reporting a case,
Both Afghanistan and Pakistan are making progress with their vaccination campaigns, but too many children are missed, partly due to the difficulties in reaching people in rural areas with poor infrastructure,
A lack of international funding for the vaccination campaigns is also a problem, says Rosenbaum.
#Ebola Vaccine Hailed As'Game Changer'In Fight Against The Virus Doctors Without Borders is calling it a"champagne moment."
"In a small trial, an experimental vaccine protected 100 percent of participants who were at high risk for the virus
vaccine or medicine,"says Dr. Marie-Paule Kieny, assistant director-general for health systems and innovation at the World health organization,
"The vaccine, called rvsv-ZEBOV, was developed by the Public health Agency of Canada. Previous studies showed it was safe.
The vaccine stops Ebola in its tracks, Kieny says.""When we talked with our colleagues who are responding to Ebola cases,
And we vaccinate, and the cases seem to disappear.'"'"In fact, there are so few cases in Guinea right
now that Kieny and her team couldn't use the standard method for testing a vaccine.
The strategy uses what's called ring vaccination. When a case crops up, the team rushes to scene andgives the vaccine to people who are close to the sick person those who are at high risk of getting the virus."So this can be the neighbors, the family, the coworkers,
"Kieny says.""This forms what is called a ring. These are the people that form the community around the case."
000 people in these so-called rings who were eligible for vaccination. They divided them up into two groups.
About half got vaccinated immediately, and the others had to wait three weeks for the shot.
In the group that got the vaccine immediately, no one got Ebola.""No cases at all. Zero,"Kieny says."
The problem is there were only 16 cases of Ebola in the group that didn't get the vaccine immediately.
That's way too small of a number to say how well the vaccine works,
But statistical analyses suggest the vaccine's efficacy is at least 70 percent, Kieny says which is still good enough to stop the spread of the disease."
preliminary results of this vaccine trial from Guinea,"says Dr. Jesse Goodman, an infectious disease specialist at Georgetown University, who once led vaccine development at the U s. Food and Drug Administration.
More data are needed to nail down the vaccine's efficacy. And there were a few issues with the design of the experiment that could have skewed the results."
"the strength of the difference between the groups that were vaccinated early and late suggests strongly to me that this vaccine is working. i
#The Future Of Cardiology Will be shown In 3-D How can you tell the difference between a good surgeon and an exceptional one?
Dassault hopes that medical device makers will also use the Living Heart Project's technology for research and development.
Recruiting Partners in Health care For the Living Heart Project, Levine has recruited so far 45 partners,
and medical device makers could pull the plug on promising research if the simulation shows a negative result."
#Highly-Effective Ebola Vaccine Could Stymie Future Outbreaks Over 27,000 cases and 11561 deaths. The statistics that tell the story of the most recent Ebola outbreak are stark,
That the conclusion of a study on an Ebola vaccine developed in a 10-month sprint by the Public health Agency of Canada
000 individuals in Guinea, are welcome news. Kimberley Steeds, an Ebola vaccine trial team member, in the Ebola vaccine laboratory, Donka Hospital in Conakry,
The vaccine is consists of a modified version of a different virus called VSV, which infects cows
The trials employed the same strategy used to contain smallpox called ing vaccination. When a person comes down with the disease,
and vaccinate anyone likely to come in contact with the patient, creating a ring of protection that hopefully keeps the virus contained
The new study evaluated the vaccine effectiveness by dividing recipients into two randomly assigned groups.
Half of the study participants received the vaccine as soon as one person they had been in contact withhether it was a relative, patient,
The other half received the vaccine after a delay of three weeks. In the 2, 000 subjects receiving the immediate vaccination treatment, not one person contracted Ebola.
Based on these results, the immediate vaccination regimen was offered to all participants starting on July 26. Even with the vaccine apparent efficacy, the trial will continue so researchers can gather more information to license the vaccine for widespread use.
The study was orchestrated by a partnership including THE WHO, the Ministry of Health of Guinea Doctors Without Borders,
and many others, comprising a monumental scientific and logistical effort. Here James Gallagher, reporting for the BBC:
The sheer scale of the 2014-15 outbreak led to an unprecedented push on vaccines and a decade work has been condensed into around 10 months.
but the vaccine trials offer, for the first time, hope that such grim statistics will never be seen again n
While other methods of disinfecting health care environments are effective, they are episodic and results are short-lived because bacteria immediately repopulate the space,
and recently granted Kenall licensing rights for the North american health care market. Kenall plans to start commercial production of the technology immediately.
a biomedical and health care technology group specializing in commercializing technologies from universities and research institutes.
bionic limbs are chiefly medical devices for now, designed to restore function. That a brain-controlled bionic leg would also promote muscle growth is stranger,
the Food and Drug Administration (FDA) announced that medical device company Wicab is allowed to market a new device that will help the blind ee.
regulatory pathway for some low-to moderate-risk medical devices that are not substantially equivalent to an already legally-marketed device, according to the press release.
Stopping the transmission of HIV is ne of the greatest public health achievements possible says Margaret Chan,
according to local public health officials. Over a one-year period, the researchers released the modified males into the local environment
Flu vaccines effectively give your immune system a antedposter based on researchersbest predictions for the mutation that year.
This work suggests that future flu vaccines could include this new kind of antibody that would be able to fight the most powerful types of influenza viruses
That might make for stronger flu vaccines --and possibly reduce the shot's frequency to once every few years e
#New Ebola Vaccine Shows 100 Percent Effectiveness In Early Tests At this time last summer, the horrific and often fatal disease Ebola was ravaging West Africa in the deadliest outbreak
But in an extremely promising medical advance, scientists are now saying that an experimental Ebola vaccine with 100 percent effectiveness has been developed.
A paper published today in The british medical journal Lancet reports that the vaccine which has been tested in Guinea
since March 2015, has shown extraordinary results so far, with 4, 123 people voluntarily vaccinated and all safe from the disease.
The joint studyonducted by international teams from the World health organization, the Guinean Health Ministry, Doctors Without Borders, the Norwegian Institute of Public health and the nonprofit Epicentre research center, among many othersas been 100 percent
effective in vaccinated individuals. his is an extremely promising development, said Dr. Margaret Chan, the Director General of the World health organization (WHO),
what known as a ing vaccination strategyto test the vaccine efficacy. This involves inoculating all known contacts of an infected individual,
John-Arne Røttingen, Director of the Division of Infectious disease Control at the Norwegian Institute of Public health, also noted in THE WHO's statement that it was this strategy in particular that has allowed for them to follow the dispersed epidemic in Guinea
more conclusive evidence is necessary to prove the vaccine ability to protect larger populations from the disease, according to THE WHO. This trait,
known as erd immunity, is especially vital in order for the vaccine to be truly successful. The trial faced some obstacles in the beginning,
because volunteers knew they were receiving the actual vaccine. This raised a number of questions on ethical and scientific grounds,
It is expected that this vaccine will likely be used to stop future outbreaks rather than vaccinate whole populations.
The speed and efficiency with which this vaccine was developed and tested in the midst of a global medical emergency is unparalleled.
Overtext Web Module V3.0 Alpha
Copyright Semantic-Knowledge, 1994-2011